McKesson Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MCK research report →
Range $845 – $1200
Price Chart
About the company
McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.
- CEO
- Brian S. Tyler
- IPO
- 1994
- Employees
- 42,300
- HQ
- Irving, TX, US
AI snapshot
Six angles, distilled from the data.
The stock remains in a powerful long-term uptrend, trading well above its 200-day moving average and only modestly below its 52-week high. That keeps the regime constructive, with pullbacks still looking like consolidation inside a larger advance rather than a broken trend.
Street sentiment is constructive: the consensus is Buy, with an average target of 998.57 and a median of 1000, though the latest target cluster has moved higher, including 1200 from UBS and 1020 from Mizuho. Recent rating actions have mostly been reaffirmations rather than downgrades, signaling steady conviction.
McKesson has a clean beat streak, going 8-for-8 on EPS with the latest quarter topping estimates by 9.3%. Next-year EPS is modeled at 44.1065 versus 38.77 TTM, so shareholders should watch whether margin discipline and distribution volume keep supporting that step-up.
Recent insider activity leans to net selling, led by multiple sales from the EVP, CIO and CTO, plus smaller sales from the controller and a director. There are also award, exempt, and in-kind entries, which read more like compensation or administrative flows than conviction buying.
Profitability is solid for a distributor: net margin is 1.12%, operating margin is 1.59%, and gross margin is 3.7%. Growth remains healthy, with revenue up 7.6% year over year and earnings up 17%, while free cash flow reached $6.9 billion on $6.155 billion of operating cash flow.
McKesson wins on scale, logistics reach, and cash generation in a low-margin distribution model, with a beta of 0.279 underscoring its defensive profile. Valuation is not cheap, at 26.21 times earnings, but the setup still screens as premium versus a typical healthcare distributor.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $123.47B
- P/E
- 27.75
- Fwd P/E
- 23.29
- PEG
- 1.32
- P/S
- 0.30
- P/B
- -31.87
- EV/EBITDA
- 17.19
- Div Yield
- 0.31%
- Gross Margin
- 3.67%
- Op Margin
- 1.62%
- Net Margin
- 1.12%
- ROE
- -161.18%
- ROIC
- 29.30%
Latest fiscal year · YoY change
- Revenue
- $403.43B+12.4%
- Gross Profit
- $14.55B+16.5%
- Op Income
- $6.45B
- Net Income
- $4.76B+44.5%
- EPS
- $38.55+49.1%
- OCF Growth
- +1.2%
- FCF Growth
- +3.5%
- 52W High
- $1121.50
- 52W Low
- $723.68
- 50D MA
- $970.56
- 200D MA
- $879.22
- Beta
- 0.28
- RSI (14)
- 59
- Avg Volume
- 801.70K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
McKesson delivered an 8% revenue increase and 18% EPS growth, then raised full-year fiscal 2027 EPS guidance on broad-based strength across its core businesses.· November 4, 2026
- Revenue rose 8% to $111 billion and adjusted EPS increased 18% to $11.68, with growth across all four operating segments.
- North American Pharmaceutical remained the main driver: revenue rose 6% to $91.4 billion and operating profit increased 22% to $1 billion, helped by specialty and GLP-1 volumes.
- Oncology and multispecialty revenue rose 24% to $15 billion; prescription technology solutions revenue rose 10% to $1.5 billion.
- Management raised fiscal 2027 adjusted EPS guidance to $45.60-$46.40 from $44.20-$45 and reiterated strong free cash flow and share repurchase activity.
- The company closed Precision Medicine Group for about $2.25 billion and signed a definitive agreement to invest about $1.4 billion for a 49% stake in Option Care Health.
McKesson reported second-quarter fiscal 2027 revenue of $111 billion, up 8% year over year, and adjusted earnings per diluted share of $11.68, up 18% year over year. Gross profit increased 10% to $3.9 billion, operating profit increased 13% to $1.9 billion, and North American Pharmaceutical operating profit rose 22% to $1 billion; oncology and multispecialty operating profit increased 8% to $427 million, prescription technology solutions operating profit increased 18% to $307 million, and MedSurg operating profit decreased 10% to $225 million. For fiscal 2027, the company raised adjusted EPS guidance to $45.60-$46.40, expects revenue growth of 6% to 10%, operating profit growth of 12% to 16%, free cash flow of approximately $4.5 billion to $4.9 billion, and about $5 billion of share repurchases. Segment outlook includes North American pharmaceutical revenue growth of 5% to 9% and operating profit growth of 14% to 18%, oncology and multispecialty revenue growth of 20% to 24% and operating profit growth of 18% to 22%, prescription technology solutions revenue growth of 2.5% to 6.5% and operating profit growth of 11% to 15%, and MedSurg revenue growth of 1% to 6% with operating profit from a 4% decline to flat.
Brian Tyler said the quarter showed continued momentum, disciplined execution, and the strength of McKesson’s diversified healthcare platform. He emphasized strategic progress in oncology, biopharma services, and community-based care, pointing to the closing of Precision Medicine Group and the proposed investment in Option Care Health as extensions of the company’s long-term strategy. His tone was confident and constructive, with repeated references to sustainable growth, operating excellence, and long-term shareholder value.
Kenny Cheung highlighted broad-based growth, citing revenue of $111 billion, gross profit of $3.9 billion, operating profit of $1.9 billion, and adjusted EPS of $11.68. He noted operating expenses rose 8% to $2.1 billion but improved as a percentage of gross profit by about 141 basis points year over year, and free cash flow was $2.9 billion with $123 million of capex. He also said McKesson ended the quarter with $6.5 billion in cash equivalents and about $11.5 billion of total liquidity, returned $990 million to shareholders during the quarter, and expects about $5 billion of share repurchases in fiscal 2027.
Analysts pressed management on how the Precision Medicine Group and Option Care Health transactions would flow through reporting segments, their margin implications, and whether Option Care could eventually become more operationally integrated. Management said PMG will be reported in oncology and multispecialty, while Option Care will be accounted for under the equity method and not within segment margins. Questions also focused on North American pharmaceutical sustainability, biosimilars, 340B policy, and the election/policy backdrop; management said the business remains durable, 340B changes are hard to model now, and it does not expect material financial impact at this time.
The call showed broad operational momentum, with growth in every segment and especially strong performance in North American pharmaceuticals, oncology, and biopharma services. Management sounded confident that the company’s scale, customer relationships, and capital deployment discipline can keep driving earnings growth above its long-term target range.
North American pharmaceutical growth may face some normalization, including lower branded pricing, quarterly variability in GLP-1 demand, and possible policy changes around 340B. MedSurg profit declined in the quarter, and management flagged continued uncertainty around customer behavior and policy implementation, especially if 340B rebate models or other regulatory changes take shape.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.9%
- Shares Outstanding
- 115.46M
- Float Shares
- 115.38M
of shares held by institutions
2,089 13F filers
Buy/sell ratio 0.20. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for MCK, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Buy | Sep 4, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Aug 10, 26 | Filing → |
| Alan ArmstrongSenate | Buy | Mar 27, 26 | Filing → |
| Jonathan JacksonHouse · IL01 | Sell | Jun 15, 26 | Filing → |
| Richard Ray LarsenHouse · WA02 | Buy | Jul 8, 26 | Filing → |
| Ritchie TorresHouse · NY15 | Buy | Jan 7, 25 | Filing → |
| Elizabeth Pannill FletcherHouse | Sell | Apr 8, 26 | Filing → |
| Markwayne MullinSenate · OK | Buy | Feb 4, 26 | Filing → |
| Markwayne MullinSenate · OK | Buy | Jan 5, 26 | Filing → |
| Markwayne MullinSenate · OK | Buy | Jan 5, 26 | Filing → |
| Jared MoskowitzHouse · FL23 | Buy | Dec 2, 25 | Filing → |
| Jared MoskowitzHouse · FL23 | Buy | Dec 2, 25 | Filing → |
| Julia LetlowHouse · LA05 | Buy | Dec 18, 24 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Dec 19, 25 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 12.10M | ▲ 73.11K |
| Blackrock, Inc. | 10.09M | ▼ 705.13K |
| Vanguard Capital Management LLC | 7.63M | ▼ 221.72K |
| State Street Corp | 5.55M | ▼ 181.26K |
| Morgan Stanley | 3.82M | ▼ 1.49M |
| Geode Capital Management, LLC | 2.98M | ▲ 154.29K |
| Franklin Templeton Inc | 2.89M | ▼ 20.05K |
| Fmr LLC | 2.86M | ▲ 726.93K |
| Vanguard Portfolio Management LLC | 2.81M | ▼ 65.54K |
| Alliancebernstein L.P. | 1.69M | ▼ 553.70K |
| Massachusetts Financial Services Co | 1.55M | ▼ 898.63K |
| Arrowstreet Capital, Limited Partnership | 1.54M | ▼ 7.57K |
Held by 2,071 ETFs
Biggest fund positions in MCK by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 5, 26 | Fraga Francisco | sell | 650 |
| Nov 3, 26 | Fraga Francisco | other | 398 |
| Nov 3, 26 | Fraga Francisco | other | 157 |
| Nov 4, 26 | Fraga Francisco | sell | 600 |
| Nov 3, 26 | Fraga Francisco | sell | 398 |
| Oct 15, 26 | Fraga Francisco | sell | 800.491 |
| Sep 8, 26 | Rutledge Napoleon B JR | sell | 111 |
| Aug 7, 26 | Srinivasan Ramesh (NMN) | other | 368 |
| Aug 10, 26 | Lerman Bradley E | sell | 301 |
| Aug 1, 26 | Srinivasan Ramesh (NMN) | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MCK coverage
Recent articles, reports, and earnings notes.

McKesson (MCK): Specialty Growth vs. Rich Valuation
McKesson posted strong Q1 growth, led by oncology and GLP-1 distribution, but the shares already price in much of the upside. The stock earns a Hold as valuation and balance-sheet constraints temper an otherwise solid earnings story.

McKesson Corporation (MCK) rises on deep earnings beat
McKesson Corporation (MCK) rises after a detailed earnings analysis shows a beat on both EPS and revenue, strong GLP-1 distribution growth, and a higher full-year outlook. The report also examines specialty and oncology momentum, analyst sentiment, and why the stock’s first reaction was muted.

McKesson Corporation (MCK) rises on earnings beats
McKesson Corporation (MCK) rises 6.1% after reporting earnings beats, lifting shares as investors react to stronger-than-expected quarterly results.
Want a deeper read on MCK?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
McKesson Corporation $MCK Holdings Reduced by Bessemer Group Inc.
defenseworld.net · Nov 20
Brokers Suggest Investing in McKesson (MCK): Read This Before Placing a Bet
zacks.com · Nov 19
Worried investors are paying up for these stocks — some with up to 49% upside, analysts say
marketwatch.com · Nov 18
Head to Head Contrast: INVO Fertility (NASDAQ:IVF) vs. McKesson (NYSE:MCK)
defenseworld.net · Nov 17
McKesson Corporation $MCK Stock: Allworth Financial LP Increases Holdings
defenseworld.net · Nov 15
McKesson: Slower FY2028 Revenue Growth Makes Today's Premium Less Attractive
seekingalpha.com · Nov 13
Here is What to Know Beyond Why McKesson Corporation (MCK) is a Trending Stock
zacks.com · Nov 11
Sales of Pharmaceuticals, GLP-1s Send McKesson Shares to New Highs
fxempire.com · Nov 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 19, 2026 · Live quote · Not investment advice